Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy

Jeroen J J van Eijk; Harry R Dalton; Paolo Ripellino; Richard G Madden; Catherine Jones; Miriam Fritz; Claudio Gobbi; Giorgia Melli; Emanuela Pasi; Jenny Herrod; Rebecca F Lissmann; Hamad H Ashraf; Mohamed Abdelrahim; Omar A B A L Masri; Montserrat Fraga; David Benninger; Thierry Kuntzer; Vincent Aubert; Roland Sahli; Darius Moradpour; Hélène Blasco-Perrin; Shahram Attarian; Rene Gérolami; Philippe Colson; Maria T Giordani; Johannes Hartl; Sven Pischke; Nan X Lin; Brendan N Mclean; Richard P Bendall; Marcus Panning; Jean-Marie Peron; Nassim Kamar; Jacques Izopet; Bart C Jacobs; Nens van Alfen; Baziel G M van Engelen

doi:10.1212/WNL.0000000000004297

Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy

Standard

Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. / van Eijk, Jeroen J J; Dalton, Harry R; Ripellino, Paolo; Madden, Richard G; Jones, Catherine; Fritz, Miriam; Gobbi, Claudio; Melli, Giorgia; Pasi, Emanuela; Herrod, Jenny; Lissmann, Rebecca F; Ashraf, Hamad H; Abdelrahim, Mohamed; Masri, Omar A B A L; Fraga, Montserrat; Benninger, David; Kuntzer, Thierry; Aubert, Vincent; Sahli, Roland; Moradpour, Darius; Blasco-Perrin, Hélène; Attarian, Shahram; Gérolami, Rene; Colson, Philippe; Giordani, Maria T; Hartl, Johannes ; Pischke, Sven; Lin, Nan X; Mclean, Brendan N; Bendall, Richard P; Panning, Marcus; Peron, Jean-Marie; Kamar, Nassim; Izopet, Jacques; Jacobs, Bart C; van Alfen, Nens; van Engelen, Baziel G M.

In: NEUROLOGY, Vol. 89, No. 9, 29.08.2017, p. 909-917.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

van Eijk, JJJ, Dalton, HR, Ripellino, P, Madden, RG, Jones, C, Fritz, M, Gobbi, C, Melli, G, Pasi, E, Herrod, J, Lissmann, RF, Ashraf, HH, Abdelrahim, M, Masri, OABAL, Fraga, M, Benninger, D, Kuntzer, T, Aubert, V, Sahli, R, Moradpour, D, Blasco-Perrin, H, Attarian, S, Gérolami, R, Colson, P, Giordani, MT, Hartl, J , Pischke, S, Lin, NX, Mclean, BN, Bendall, RP, Panning, M, Peron, J-M, Kamar, N, Izopet, J, Jacobs, BC, van Alfen, N & van Engelen, BGM 2017, 'Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy', NEUROLOGY, vol. 89, no. 9, pp. 909-917. https://doi.org/10.1212/WNL.0000000000004297

APA

van Eijk, J. J. J., Dalton, H. R., Ripellino, P., Madden, R. G., Jones, C., Fritz, M., Gobbi, C., Melli, G., Pasi, E., Herrod, J., Lissmann, R. F., Ashraf, H. H., Abdelrahim, M., Masri, O. A. B. A. L., Fraga, M., Benninger, D., Kuntzer, T., Aubert, V., Sahli, R., ... van Engelen, B. G. M. (2017). Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. NEUROLOGY, 89(9), 909-917. https://doi.org/10.1212/WNL.0000000000004297

Vancouver

van Eijk JJJ, Dalton HR, Ripellino P, Madden RG, Jones C, Fritz M et al. Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. NEUROLOGY. 2017 Aug 29;89(9):909-917. https://doi.org/10.1212/WNL.0000000000004297

Bibtex

@article{3a2510ba46e645cdbe15e0d5332b381d,

title = "Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy",

abstract = "OBJECTIVE: To determine the clinical phenotype and outcome in hepatitis E virus-associated neuralgic amyotrophy (HEV-NA).METHODS: Cases of NA were identified in 11 centers from 7 European countries, with retrospective analysis of demographics, clinical/laboratory findings, and treatment and outcome. Cases of HEV-NA were compared with NA cases without evidence of HEV infection.RESULTS: Fifty-seven cases of HEV-NA and 61 NA cases without HEV were studied. Fifty-six of 57 HEV-NA cases were anti-HEV IgM positive; 53/57 were IgG positive. In 38 cases, HEV RNA was recovered from the serum and in 1 from the CSF (all genotype 3). Fifty-one of 57 HEV-NA cases were anicteric; median alanine aminotransferase 259 IU/L (range 12-2,961 IU/L); in 6 cases, liver function tests were normal. HEV-NA cases were more likely to have bilateral involvement (80.0% vs 8.6%,p< 0.001), damage outside the brachial plexus (58.5% vs 10.5%,p< 0.01), including phrenic nerve and lumbosacral plexus injury (25.0% vs 3.5%,p= 0.01, and 26.4% vs 7.0%,p= 0.001), reduced reflexes (p= 0.03), sensory symptoms (p= 0.04) with more extensive damage to the brachial plexus. There was no difference in outcome between the 2 groups at 12 months.CONCLUSIONS: Patients with HEV-NA are usually anicteric and have a distinct clinical phenotype, with predominately bilateral asymmetrical involvement of, and more extensive damage to, the brachial plexus. Involvement outside the brachial plexus is more common in HEV-NA. The relationship between HEV and NA is likely to be causal, but is easily overlooked. Patients presenting with NA should be tested for HEV, irrespective of liver function test results. Prospective treatment/outcome studies of HEV-NA are warranted.",

keywords = "Adult, Aged, Aged, 80 and over, Brachial Plexus, Brachial Plexus Neuritis, Europe, Female, Hepatitis Antibodies, Hepatitis E, Hepatitis E virus, Humans, Immunoglobulin G, Immunoglobulin M, Liver Function Tests, Male, Middle Aged, Phenotype, RNA, Viral, Retrospective Studies, Treatment Outcome, Young Adult, Journal Article, Multicenter Study",

author = "{van Eijk}, {Jeroen J J} and Dalton, {Harry R} and Paolo Ripellino and Madden, {Richard G} and Catherine Jones and Miriam Fritz and Claudio Gobbi and Giorgia Melli and Emanuela Pasi and Jenny Herrod and Lissmann, {Rebecca F} and Ashraf, {Hamad H} and Mohamed Abdelrahim and Masri, {Omar A B A L} and Montserrat Fraga and David Benninger and Thierry Kuntzer and Vincent Aubert and Roland Sahli and Darius Moradpour and H{\'e}l{\`e}ne Blasco-Perrin and Shahram Attarian and Rene G{\'e}rolami and Philippe Colson and Giordani, {Maria T} and Johannes Hartl and Sven Pischke and Lin, {Nan X} and Mclean, {Brendan N} and Bendall, {Richard P} and Marcus Panning and Jean-Marie Peron and Nassim Kamar and Jacques Izopet and Jacobs, {Bart C} and {van Alfen}, Nens and {van Engelen}, {Baziel G M}",

note = "{\textcopyright} 2017 American Academy of Neurology.",

year = "2017",

month = aug,

day = "29",

doi = "10.1212/WNL.0000000000004297",

language = "English",

volume = "89",

pages = "909--917",

journal = "NEUROLOGY",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

RIS

TY - JOUR

T1 - Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy

AU - van Eijk, Jeroen J J

AU - Dalton, Harry R

AU - Ripellino, Paolo

AU - Madden, Richard G

AU - Jones, Catherine

AU - Fritz, Miriam

AU - Gobbi, Claudio

AU - Melli, Giorgia

AU - Pasi, Emanuela

AU - Herrod, Jenny

AU - Lissmann, Rebecca F

AU - Ashraf, Hamad H

AU - Abdelrahim, Mohamed

AU - Masri, Omar A B A L

AU - Fraga, Montserrat

AU - Benninger, David

AU - Kuntzer, Thierry

AU - Aubert, Vincent

AU - Sahli, Roland

AU - Moradpour, Darius

AU - Blasco-Perrin, Hélène

AU - Attarian, Shahram

AU - Gérolami, Rene

AU - Colson, Philippe

AU - Giordani, Maria T

AU - Hartl, Johannes

AU - Pischke, Sven

AU - Lin, Nan X

AU - Mclean, Brendan N

AU - Bendall, Richard P

AU - Panning, Marcus

AU - Peron, Jean-Marie

AU - Kamar, Nassim

AU - Izopet, Jacques

AU - Jacobs, Bart C

AU - van Alfen, Nens

AU - van Engelen, Baziel G M

PY - 2017/8/29

Y1 - 2017/8/29

N2 - OBJECTIVE: To determine the clinical phenotype and outcome in hepatitis E virus-associated neuralgic amyotrophy (HEV-NA).METHODS: Cases of NA were identified in 11 centers from 7 European countries, with retrospective analysis of demographics, clinical/laboratory findings, and treatment and outcome. Cases of HEV-NA were compared with NA cases without evidence of HEV infection.RESULTS: Fifty-seven cases of HEV-NA and 61 NA cases without HEV were studied. Fifty-six of 57 HEV-NA cases were anti-HEV IgM positive; 53/57 were IgG positive. In 38 cases, HEV RNA was recovered from the serum and in 1 from the CSF (all genotype 3). Fifty-one of 57 HEV-NA cases were anicteric; median alanine aminotransferase 259 IU/L (range 12-2,961 IU/L); in 6 cases, liver function tests were normal. HEV-NA cases were more likely to have bilateral involvement (80.0% vs 8.6%,p< 0.001), damage outside the brachial plexus (58.5% vs 10.5%,p< 0.01), including phrenic nerve and lumbosacral plexus injury (25.0% vs 3.5%,p= 0.01, and 26.4% vs 7.0%,p= 0.001), reduced reflexes (p= 0.03), sensory symptoms (p= 0.04) with more extensive damage to the brachial plexus. There was no difference in outcome between the 2 groups at 12 months.CONCLUSIONS: Patients with HEV-NA are usually anicteric and have a distinct clinical phenotype, with predominately bilateral asymmetrical involvement of, and more extensive damage to, the brachial plexus. Involvement outside the brachial plexus is more common in HEV-NA. The relationship between HEV and NA is likely to be causal, but is easily overlooked. Patients presenting with NA should be tested for HEV, irrespective of liver function test results. Prospective treatment/outcome studies of HEV-NA are warranted.

AB - OBJECTIVE: To determine the clinical phenotype and outcome in hepatitis E virus-associated neuralgic amyotrophy (HEV-NA).METHODS: Cases of NA were identified in 11 centers from 7 European countries, with retrospective analysis of demographics, clinical/laboratory findings, and treatment and outcome. Cases of HEV-NA were compared with NA cases without evidence of HEV infection.RESULTS: Fifty-seven cases of HEV-NA and 61 NA cases without HEV were studied. Fifty-six of 57 HEV-NA cases were anti-HEV IgM positive; 53/57 were IgG positive. In 38 cases, HEV RNA was recovered from the serum and in 1 from the CSF (all genotype 3). Fifty-one of 57 HEV-NA cases were anicteric; median alanine aminotransferase 259 IU/L (range 12-2,961 IU/L); in 6 cases, liver function tests were normal. HEV-NA cases were more likely to have bilateral involvement (80.0% vs 8.6%,p< 0.001), damage outside the brachial plexus (58.5% vs 10.5%,p< 0.01), including phrenic nerve and lumbosacral plexus injury (25.0% vs 3.5%,p= 0.01, and 26.4% vs 7.0%,p= 0.001), reduced reflexes (p= 0.03), sensory symptoms (p= 0.04) with more extensive damage to the brachial plexus. There was no difference in outcome between the 2 groups at 12 months.CONCLUSIONS: Patients with HEV-NA are usually anicteric and have a distinct clinical phenotype, with predominately bilateral asymmetrical involvement of, and more extensive damage to, the brachial plexus. Involvement outside the brachial plexus is more common in HEV-NA. The relationship between HEV and NA is likely to be causal, but is easily overlooked. Patients presenting with NA should be tested for HEV, irrespective of liver function test results. Prospective treatment/outcome studies of HEV-NA are warranted.

KW - Adult

KW - Aged

KW - Aged, 80 and over

KW - Brachial Plexus

KW - Brachial Plexus Neuritis

KW - Europe

KW - Female

KW - Hepatitis Antibodies

KW - Hepatitis E

KW - Hepatitis E virus

KW - Humans

KW - Immunoglobulin G

KW - Immunoglobulin M

KW - Liver Function Tests

KW - Male

KW - Middle Aged

KW - Phenotype

KW - RNA, Viral

KW - Retrospective Studies

KW - Treatment Outcome

KW - Young Adult

KW - Journal Article

KW - Multicenter Study

U2 - 10.1212/WNL.0000000000004297

DO - 10.1212/WNL.0000000000004297

M3 - SCORING: Journal article

C2 - 28768846

VL - 89

SP - 909

EP - 917

JO - NEUROLOGY

JF - NEUROLOGY

SN - 0028-3878

IS - 9

ER -